1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Summary of the multivariate CPH models with age and surgical extent (subtotal, gross total resection) as covariates
Edge Time PFS P Value HR 95% CI OS P Value HR 95% CI
EC_100% Postbevacizumab .009^{^a} 0.37 0.18–0.78 .046^{^b} 0.42 0.18–0.98
EC_75% Postbevacizumab .013^{^b} 0.33 0.13–0.79 .041^{^b} 0.34 0.12–0.96
EC_50% Postbevacizumab .015^{^b} 0.29 0.10–0.78 .026^{^b} 0.25 0.07–0.85
EC_25% Postbevacizumab .018^{^b} 0.21 0.05–0.77 .022^{^b} 0.16 0.03–0.77
FLAIR_VOL Postbevacizumab .872 1.000 1.000–1.000 .204 1.000 1.000–1.000
CE_VOL Postbevacizumab .758 1.000 1.000–1.000 .258 1.000 1.000–1.000
ΔEC_100% Pre- and postbevacizumab .018^{^b} 2.81 1.92–6.65 .033^{^b} 2.98 1.09–8.16
ΔEC_75% Pre- and postbevacizumab .039^{^b} 2.75 1.05–7.19 .050 3.06 0.99–9.39
ΔEC_50% Pre- and postbevacizumab .058 2.91 0.96–8.08 .054 3.54 0.97–12.88
ΔEC_25% Pre- and postbevacizumab .067 3.74 0.090–15.42 .056 4.76 0.95–23.64
ΔFLAIR_VOL Pre- and postbevacizumab .360 1.000 1.000–1.000 .487 1.000 1.000–1.000
ΔCE_VOL Pre- and postbevacizumab .951 1.000 1.000–1.000 .926 1.000 1.000–1.000
Note:—CPH indicates Cox proportional hazards; HR, hazard ratio.
↵a P < .01.
↵b P < .05.